CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.D., spoke to Newswise LIVE recently to discuss the following:

• What is head and neck cancer? Can you provide us with a short overview?

• How are cancers in the head and neck region treated today? How difficult is the standard-of-care for these patients?

MORE ON THIS TOPIC